The Greek pharmaceutical market is currently witnessing a wide-range of changes, with Novartis taking the lead in the market, outpacing Pfizer and Sanofi-Aventis in an environment of lower sales volume and higher sales value, a report by IMS stated on Wednesday.
The report, measuring the sales of pharmaceutical enterprises to pharmacies - the off-hospital pharmaceuticals market - in the first five months of the year, showed that sales volume was down 0.3 pct, compared with the corresponding period last year, while sales value was up 6.8 pct reflecting the sales of new, pricier medicines.
Novartis, with a 17.7 pct rise in the value of sales, raised its market share to 8.0 pct, leaving Pfizer behind in third position with a 7.9-pct market share and Sanofi-Aventis.
Vianez, representing Merck, among others, recorded a 4.2-pct rise in sales with a market share of 6.4 pct. Boehringer Ingelheim is the only multinational group to maintain a production unit in Greece and remains the biggest exporter of Greek pharmaceutical products.
